Raul Shah discusses expectations for Hims & Hers (HIMS) into earnings after Monday's closing bell. He believes the telehealth company is well-positioned thanks to the GLP-1 wave, arguing investors are severely underestimating how many Americans will use these drugs. Raul points to a key acquisition as another buoy that will drive profits long-term for Hims & Hers. Tom White turns to an example options trade for the stock. See Raul's recent interview with Marley Kayden on Market Matters: https://schwabnetwork.com/video/market-matters-ep-12-how-hims-could-benefit-from-fda-changes